Ebola Lurking in Brain Fluid Kills Monkeys Weeks After Recovery

New research reveals where the virus was hiding and hints at how to truly purge it from the body.

Written byDan Robitzski
| 4 min read
Artist’s rendering of a light purple Ebola virus looping around itself that’s surrounded by red blood cells
Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

A new study in macaques sheds light on how the Ebola virus can persist in the brains of survivors even after they’ve been vaccinated, treated with FDA-approved monoclonal antibody therapies, or both.

There’s a growing body of evidence suggesting that Ebola can lurk in the body for long periods of time, evading the immune system as well as available therapeutics. Reports from Ebola outbreaks document survivors that relapse, falling ill and sometimes dying months or even years after they’ve recovered from their acute illness. Macaque and human studies have also shown that the Ebola virus can persist long-term in the eyes, brain, and testes of survivors. Research published today (February 9) in Science Translational Medicine sheds new light on this process: scientists found the virus in the ventricles—cavities in the brain that produce and circulate cerebrospinal fluid (CSF)—of several macaques that were treated for and appeared to have made complete ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • black and white image of young man in sunglasses with trees in background

    Dan is an award-winning journalist based in Los Angeles who joined The Scientist as a reporter and editor in 2021. Ironically, Dan’s undergraduate degree and brief career in neuroscience inspired him to write about research rather than conduct it, culminating in him earning a master’s degree in science journalism from New York University in 2017. In 2018, an Undark feature Dan and colleagues began at NYU on a questionable drug approval decision at the FDA won first place in the student category of the Association of Health Care Journalists' Awards for Excellence in Health Care Journalism. Now, Dan writes and edits stories on all aspects of the life sciences for the online news desk, and he oversees the “The Literature” and “Modus Operandi” sections of the monthly TS Digest and quarterly print magazine. Read more of his work at danrobitzski.com.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies